IIPLA Editorial

Insight, analysis, and practical IP commentary.

Case-aware analysis, policy context, enforcement lessons, and professional guidance for IP practitioners and business leaders.

All topics AI & IP Analysis Brands Copyright Counterfeiting Enforcement Licensing Litigation Patents Policy

Showing the blog archive for Wed, Apr 29, 2026.

Return to latest commentary

Licensing #Patent Settlement

GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech

GSK benefits financially from a settlement with BioNTech, CureVac, and Pfizer over mRNA patent disputes, including upfront payments and future royalties.

IIPLA News DeskWednesday, April 29, 2026